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A B S T R A C T
Purpose
Active surveillance is increasingly accepted as a treatment option for favorable-risk prostate
cancer. Long-term follow-up has been lacking. In this study, we report the long-term outcome of
a large active surveillance protocol in men with favorable-risk prostate cancer.
Patients and Methods
In a prospective single-arm cohort study carried out at a single academic health sciences center, 993 men
with favorable- or intermediate-risk prostate cancer were managed with an initial expectant approach.
Intervention was offered for a prostate-specific antigen (PSA) doubling time of less than 3 years, Gleason
score progression, or unequivocal clinical progression. Main outcomemeasures were overall and disease-
specific survival, rate of treatment, and PSA failure rate in the treated patients.
Results
Among the 819 survivors, the median follow-up time from the first biopsy is 6.4 years (range, 0.2
to 19.8 years). One hundred forty-nine (15%) of 993 patients died, and 844 patients are alive
(censored rate, 85.0%). There were 15 deaths (1.5%) from prostate cancer. The 10- and 15-year
actuarial cause-specific survival rates were 98.1% and 94.3%, respectively. An additional 13
patients (1.3%) developed metastatic disease and are alive with confirmed metastases (n  9) or
have died of other causes (n  4). At 5, 10, and 15 years, 75.7%, 63.5%, and 55.0% of patients
remained untreated and on surveillance. The cumulative hazard ratio for nonprostate-to-prostate
cancer mortality was 9.2:1.
Conclusion
Active surveillance for favorable-risk prostate cancer is feasible and seems safe in the 15-year time
frame. In our cohort, 2.8% of patients have developed metastatic disease, and 1.5% have died of
prostate cancer. This mortality rate is consistent with expected mortality in favorable-risk patients
managed with initial definitive intervention.
J Clin Oncol 33:272-277. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Active surveillance for favorable-risk localized pros-
tate cancer may reduce the risk of overtreatment of
clinically insignificant prostate cancer while retain-
ing the option of definitive therapy for patients who
are reclassified over time as higher risk.
Beginning in 1995, we initiated a prospective
clinical trial to evaluate active surveillance, in which
the decision to intervene was determined by
prostate-specific antigen (PSA) kinetics and/or his-
tologic progression. Our initial cohort was first re-
ported in 2002,1,2 and a follow-up was reported in
2010 of 450 patients with 8-year follow-up.3 This
report represents a reanalysis with 993 patients and
up to 16 years of follow-up.
PATIENTS AND METHODS
A prospective, single-arm cohort study was initiated in
November 1995 to assess the feasibility of an observation
protocol with selective delayed intervention using PSA
kinetics and/or histologic progression as triggers for inter-
vention. Favorable and selected intermediate-risk patients
were offered an initial surveillance approach. PSA was
performed every 3 months for 2 years and then every 6
months in stable patients. A confirmatory biopsy was per-
formed within 12 months of the initial biopsy and then
every 3 to 4 years until the patient reached 80 years old.
Biopsies were performed according to the Vienna nomo-
gram.4 Patients were reclassified as higher risk and offered
radical intervention if they met the following criteria:
PSA doubling time (DT) of less than 3 years (from
1996 to 2008). Beginning in 2009, adverse PSA kinetics
were discontinued as a sole trigger for intervention; rather,
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they were an indication for closer scrutiny, either with repeat biopsies or a
multiparametric magnetic resonance imaging (MRI).
Histologic upgrade on repeat prostate biopsy. Patients had an eight- to
14-core biopsywithin a year after the initial biopsy. This targeted the site of the
original positive core and the anterior and anterolateral zones. Subsequent
biopsies were performed every 3 to 4 years.
Clinical progression as defined by development of an unequivocal
palpable nodule during surveillance confirmed histologically to be
disease progression.
Between 1995 and 1999, the study was offered to all low-risk patients
(Gleason score 6 and PSA 10 ng/mL) and to patients older than age 70
years with PSA 15 ng/mL or Gleason score 34 (7). Since January 2000,
the studywas restricted to low-risk patients (Gleason score 6 and PSA 10
ng/mL) or patients with favorable intermediate-risk disease (PSA 10 to 20
ng/mL and/or Gleason score 34) with significant comorbidities and a life
expectancy of less than 10 years. The phase II clinical trial was approval by the
SunnybrookResearchEthicsBoard.From1995 to2002, informedconsentwas
obtained from each participant. Beginning in 2003, active surveillance was
offered as a management option to patients without a formal consent form.
The same data were collected prospectively (also approved by the Research
Ethics Board).
Statistical Methods
Survival analysis was performed in all patients, including Kaplan-Meier
overall survival (OS), cause-specific survival (CSS), time to stopping surveil-
lance, and time toPSA failure.Median follow-up timewas calculatedusing the
reverse Kaplan-Meier method.5 PSA failure was defined as a PSA more than
0.2 ng/mL after surgery and PSA nadir plus 2 ng/mL after radiation.
PSA DT was calculated using the general linear mixed model method.6
The Hosmer-Lemeshow test was performed for goodness-of-fit. Internal val-
idation of the two final multivariable models was performed using the non-
parametric bootstrapmethod.
RESULTS
Patient Population
The current cohort (data lock was May 5, 2013) comprises 993
patients.Medianage is67.8years(range,41to89years).Twohundredsix
patients have been observed for more than 10 years and 50 patients for
more than15years.Amongall 993patients, 149died, 819were alive, and
25 (2.5%) were lost to follow-up. The median follow-up time from the
initialcancerdiagnosis is6.4years(range,0.2to19.8years).Tenpercentof
patientswere entered onto the studywithin the previous 2 years.
The distribution of patients by stage, grade, and PSA is shown in
AppendixTableA1 (online only) andTable 1. Five percent of patients
werediagnosedafter a transurethral resectionof theprostate, 74%had
T1c disease, 17% had a palpable nodule, and 4% were classified as
having unknown stage. Baseline PSAwas less than 2.5 ng/mL in 14%,
2.5 to 5 ng/mL in 30%, 5 to 10 ng/mL in 43%, greater than 10 ng/mL
in 11%, and unknown in 2% of patients. Eighty-four percent of
patients had aGleason score of 6, and 13%had aGleason score of 7
(34). Baseline Gleason score could not be ascertained in 2% of
patients (whose original biopsies were performed outside of our insti-
tution 10 years ago). Twenty-one percent of patients were interme-
diate risk, of whom 3% had both PSA more than 10 ng/mL and
Gleason score of 7.
Mortality Outcomes
OS is shown inFigure 1.Among993patients, 149patients (15%)
died, and 844 patients were alive (censored rate, 85%). The OS range
was0.2 to20.2 years.The10- and15-yearOSrateswere80%and62%,
respectively. In univariable and multivariable Cox proportional haz-
ards regression analyses, four significant predictive factors at baseline
were found and remained in the multivariable model, namely, age
70 years (hazard ratio [HR], 2.87; 95% CI, 1.88 to 4.38; P  .001),
transrectal ultrasonography volume (HR, 0.983; 95% CI, 0.973 to
0.993;P .001),Gleasonscoremore than6(HR,1.70; 95%CI,1.14 to
2.55; P  .010), and PSA values (log scale; HR, 1.52; 95% CI, 1.00
to 2.31; P .048).
CSS is shown in Figure 2. Among 993 patients, there were 15
deaths (1.5%) from prostate cancer, and 978 patients were alive or
suffered death from other causes. All 15 patients who died of prostate
cancer had confirmed metastases before death. An additional 13 pa-
tients (1.3%) with confirmed metastases are alive (n 9) or died of
well-documented other causes (n 4). Thus, 2.8% (n 28) of the
entire cohort has developed metastatic disease. Median follow-up
time for thepatientswithmetastaticdiseasewas9.6 years (range, 2.3 to
16.4 years). Median time to metastasis was 7.3 years (95% CI, 5.81 to
8.76 years). Twelve (44%) of the 28 patients with metastases had a
Gleason score of 34 (7) at diagnosis (v 13% of the overall cohort).
Seven patients (26%) fulfilled Epstein criteria for very low risk.
Of the 15 patients who died of prostate cancer, seven patients re-
ceived radiotherapy (RT), two had a radical prostatectomy (RP), four
received androgen-deprivation therapy as sole therapy, and two refused
treatmentuntilmetastaticdiseasedeveloped.The10-and15-yearactuar-
ialCSSrateswere98%,and94%, respectively.CSSdidnotdifferbetween
patients less than or greater than age 70 years (Appendix Fig A1, online
only;P .18).Onlytwoof28patientswhodevelopedmetastasiswerenot
upgraded to Gleason score  7 before developing metastatic disease.
Neither of these twopatients had surgical grading.
Table 1. Baseline Gleason score and PSA of Patients
Gleason Score
Patients by PSA Patients by Age
0 to 2.5
ng/mL
 2.5 to 5
ng/mL
 5 to 10
ng/mL
 10 to
15 ng/mL
 15 ng/
mL Unknown Total
 70
Years
 70
Years
No. % No. % No. % No. % No. % No. % No. % No. % No. %
 6 124 89 267 90 349 82 62 70 15 71 20 80 837 84 536 90 301 75
7 13 9 21 7 64 15 25 27 5 23 4 16 132 13 45 8 87 22
Not available 3 2 9 3 9 2 1 1 1 5 1 4 24 24 14 2 10 3
Total 140 297 422 88 21 25 993 595 398
Abbreviation: PSA, prostate-specific antigen.
Low-risk group.
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Univariable analysis was used to determine which factors were
associatedwith early developmentofmetastasis. Thosewith aPSADT
of less than3years experiencedprogressionearlier than thegroupwith
longerPSADT(median, 5.12 v9.23 years, respectively;P .002). The
finding of a Gleason score of 8 to 10 on confirmatory biopsy was
associatedwith early progression tometastasis (Gleason score of 6 v 8,
P .034; Gleason score of 7 v 8, P .023).
The cumulative HR for non–prostate cancer to prostate cancer
death in all patients was 9.2 (95% CI, 5.4 to 15.6; Appendix Fig A2,
online only). Appendix Figure A3 (online only) shows this HR strati-
fied by age  or less than 70 years. As expected, the risk of non–
prostate cancermortalitywas higher inmen 70 years old (HR, 11.5;
95% CI, 5.8 to 22.8), although even in men younger than age 70, the
riskofnon–prostate cancermortalitywas almost six timeshigher than
that of prostate cancer mortality (HR, 5.8; 95%CI, 2.4 to 13.8).
Intervention
Todate, 267 (27%)of the 993patients havebeen treated.Time to
treatment is shown in Figure 3. At 5, 10, 15, and 20 years, 75.7%,
63.5%,55.0%,and55.0%ofpatients remainuntreatedandonsurveil-
lance, respectively. The reasons for discontinuing surveillance are
listed in Table 2. PSA DT and grade of progression were the most
common reasons for starting treatment. The choice of RT, RP, or
androgen-deprivation therapy was based on age, general health, and
patient preference.
Appendix Table A2 (online only) shows the univariable andmulti-
variable analysis of factors predicting for the likelihood of being reclassi-
fiedashigherrisk.Age,tumorstage(vT2),PSAvalues,Gleasonscore
( v 6), number of cores involved at baseline and on confirmatory
biopsy, and prostatitis on biopsy all correlated with risk reclassification.
The likelihood of being treated was related to Gleason score (P .005;
oddsratio[OR],1.72)andbaseline tumorcategoryT2a(P .001;OR,
1.96)butnottobaselinePSA(v10ng/mL;P .59)intheunivariable
analysis. In themultivariable analysis, Gleason score at 1 year (P .001)
andbaselinePSAvalues (log scale;P .046)were significantly predictive
for intervention. This final multivariable model showed no evidence of
lack of fit based on the Hosmer-Lemeshow statistic (P  .235). The
probability ofmisclassificationwas 21.2%.
Post-treatment PSA levels were available for 249 patients (93%)
treated after a period of surveillance, whereas the remaining 18 patients
were treated elsewhere and post-treatment PSA levels could not be ob-
tained. PSA failure has been calculated both from thedate of diagnosis of
prostate cancer,using theentire cohort as thedenominator, and fromthe
Ov
er
al
l S
ur
vi
va
l
(p
ro
ba
bi
lit
y)
Time (years)
No. at risk 993 889 712 532 353 206 132 70 22
14 16121086420
1.0
0.8
0.6
0.4
0.2
Fig 1. Kaplan-Meier overall survival curve with 95% CIs in all patients.
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Fig 2. Kaplan-Meier cause-specific survival curve with 95% CIs in all patients.
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Fig 3. Time to intervention with 95% CIs in all patients.
Table 2. Reasons for Intervention on Surveillance
Reason for Intervention/
Treatment
No. of
Patients
% of Patients
Treated Patients
(n  267)
Total Cohort
(N  993)
Short PSA doubling time 116 43.5 11.7
Grade progression 94 35 9.5
Patient preference 16 6 1.6
Stage progression 8 3 0.8
Biopsy volume progression 6 2 0.6
Ureteral obstruction 3 1 0.3
Ultrasound lesion volume
increase  2
1 0.4 0.1
Other 2 0.8 0.2
Not reported 21 7.9 2
Total 267 100 27
Abbreviation: PSA, prostate-specific antigen.
Klotz et al
274 © 2014 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by Queen's University Belfast on January 29, 2018 from 143.117.193.021
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
dateoftreatmentusingthetreatedpatientsasthedenominator.Ofthe249
patients, 63 (25%) experienced a PSA failure, representing 6% of the
overall cohort (63 of 993 patients). As a proportion of the entire surveil-
lance cohort (Fig 4), the 5- and 10-year biochemical disease-free survival
rates fromthe timeofdiagnosiswere 97.2%and89.8%, respectively.The
5- and 10-year biochemical disease-free survival rates from the time of
treatment as a proportion of the treated patients were 77% and 60%,
respectively (Appendix Fig A4, online only). Of the 75 patients treated
withRPand148patients treatedwithRT,25%and24%experiencedPSA
failure, respectively.Thebiochemical noevidenceofdisease survival rates
afterRPat 5, 10, and15years fromthedateof treatmentwere 80%,65%,
and 54%, respectively; in patients treated with RT, the rates were 79%,
60%,and48%,respectively.Thisdifferenceinbiochemicalnoevidenceof
disease failurebetweenRPandRTwasnot significant (P .60),notwith-
standingthedifference indefinitionsofPSAfailurebetweenthesegroups.
ThePSA failure rates in the treated patients at 5, 10, and 14 years from
the date of diagnosis as a proportion of thewhole cohort were 3%, 10%,
and 22%, respectively.
AppendixTableA3 lists theunivariable andmultivariable factors
predicting for biochemical failure after intervention. Factors predict-
ing for PSA failurewere age, tumor stage, log PSA at baseline, baseline
Gleason score, PSADT, andpercentage andnumberof cores involved
on the initial biopsy. Neither the presence of prostatic intraepithelial
neoplasia nor atypical small acinar proliferation predicted for bio-
chemical failure after treatment. Biopsy findings were a trigger for
intervention in 35% of the treated patients. However, number of
biopsies, Gleason score, and number of cores involved on the biopsy
triggering intervention were not significantly predictive for biochem-
ical failure after treatment. Patients with longer duration of surveil-
lancehad a lower risk of biochemical failure after treatment (OR, 0.82;
95% CI, 0.74 to 0.89). A PSA DT of less than 3 years was associated
with a 7.8-fold (95% CI, 4.4 to 13.7-fold) greater likelihood of bio-
chemical recurrence after treatment compared with a PSADT of 3
years. Among patientswith a PSADTof less than 3 years, the absolute
value of theDT (ie, 0 to 1, 1 to 2, or 2 to 3 years) was not predictive. In
the multivariable analysis, duration of active surveillance (P .001)
andbaselinePSAvalues (log scale;P .014)were significantly predic-
tive for PSA failure after definitive therapy. This final multivariable
model showed no evidence of lack of fit based on the Hosmer-
Lemeshow statistic (P  .902). The probability of misclassification
was only 6.5%.
DISCUSSION
Active surveillancehasbeen increasinglyacceptedasa safeapproachto
favorable-risk prostate cancer in the 5- to 10-year time frame. In this
series, follow-up is extended to 16 years. Two hundred six patients
have been observed for more than 10 years and 60 patients for more
than 15 years. The 10- and 15-year actuarial CSS rates are 98.1% and
94.3%, respectively. Only 15 patients in this cohort of 993 patients
have died of prostate cancer, and an additional 13 patients have devel-
opedmetastatic disease. The OS rate is 85.0%. Younger patients were
not at increased risk for prostate cancer mortality. Post hoc power
analysis determined that our study achieved greater than 99% power
to contrast the 15-year prostate cancermortality between5.7%(Fig 2)
in our study and 22% in the study by Albertsen et al.7
There are seven active surveillance series in the literature, includ-
ing this one (Table 2), constitutingmore than 4,000 patients.3,8-12 OS
in the combined cohort is 93%, and the disease-specific survival is
99.7%. One third of patients have been treated definitively. The data
reported here extend the confidence regarding the indolent and non-
lethal nature of most favorable-risk prostate cancer beyond 15 years.
Twenty-five percent of the patients in this study fulfilled the
D’Amico criteria for intermediate risk.Nonetheless, the 15-year pros-
tate cancer mortality is low. This supports the concept that in a
screened population, selected men older than age 70 years with
intermediate-risk prostate cancer are candidates for surveillance.
Popiolek et al13 reported prostate cancer mortality in low-
grade patients managed with watchful waiting (with no option of
radical intervention) observed for more than 30 years. In the
low-risk group, prostate cancer mortality was 13% overall and was
11% and 28% at 15 and 20 years, respectively. These patients,
importantly, were not offered delayed definitive intervention. This
likely explains the two-fold greater 15-year prostate cancermortal-
ity in the experience of Popiolek et al13 compared with this active
surveillance cohort (11% v 5.7%, respectively).
The PSA progression rates among the 249 evaluable patients
offered definitive local therapy 5 and 10 years after the therapeutic
interventionwere 23%and41%, respectively.Moremeaningfully, the
rates of all patients on surveillance who were treated and went on to
experience subsequent PSA failure were 2.8% and 10.2% at 5 and 10
years after diagnosis, respectively. This is comparable to the outcome
of radiation and surgery for favorable-risk disease.
A PSA DT of less than 3 years as the trigger for intervention was
associated with a 7.8-fold greater risk of PSA progression after defini-
tive therapy compared with patients with a PSA DT  3 years (in
whom grade progression was the usual indication for intervention).
This supports theconcept that aPSADTof less than3years is amarker
for aggressive disease. It demonstrates sensitivity but lacks specific-
ity.14 We previously reported that in 300 men who remained on
surveillance long term, none of whom had clinical or pathologic pro-
gression, 50% had at least one trigger for intervention at some point
during the follow-up period.15 Therefore, relying on PSA kinetics to
determine who to treat would result in significant overtreatment.
The PSA failure rate of 25% in the treated patients at 10 years com-
pares favorably with our previous report, where it was approximately
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50%.3 That includedmany patients from the late 1990s. Because confir-
matorybiopsieswerenotmandatoryuntil2002, thosemenwhowererisk
reclassified with higher-grade disease were diagnosed later. They were
treated inmost caseswith 66Gyof radiation, a dose that today is consid-
ered subtherapeutic, andweremanagedon surveillance in aperiodwhen
experiencewith this approachwas limited and decisionmakingmore ad
hoc. Ten percent of the overall cohort experienced post-treatment PSA
failure, consistent with PSA failure after radiation or surgery in a
favorable-risk cohort.16,17 Furthermore, most of the surgically treated
patients with PSA failure received effective salvage RT. Over 1,000 boot-
strap samples, the SEs of coefficients for significant factors predicting for
therapeutic interventionandforPSAfailureafterdefinitive therapy in the
finalmultivariablemodels can be found in Appendix Tables A2 andA3.
Compared with the original model estimates (SE) for those significant
predictive factors in themultivariable analyses, thebiasof estimatororSE
was similar between the original SE and the bootstrapping SE for the two
models. Therefore, the reproducibility of themodels was confirmed.We
conclude that these clinical parameters contributed significantly to the
therapeutic intervention and to the PSA failure after treatment after vali-
dation by the bootstrap approach.
Active surveillance is an evolving strategy. The major limitation is
that a significant proportion of patients diagnosed with Gleason score 6
cancer harbor higher-grade disease. The ability to identify earlier and
moreaccuratelythosepatientswithoccultGleasonpattern4and5cancer
is likely to result in improved results, including a decrease in PSA
failure rates in the risk-reclassified patients and lower metastasis
and mortality rates. This would also offer reassurance to those
patients not found to have higher-risk disease. Bothmultiparamet-
ricMRI andmolecular biomarkers show promise in providing this
opportunity. We and others have incorporated MRI into patient
decision making. However, the cohort described here, 97% of
whom remained free of metastatic disease or prostate cancer mor-
tality and 55% of whom avoided any treatment, was largely man-
aged without the benefit of MRI.
This study had some limitations. Patients were graded according to
theGleason grading systemat the timeof diagnosis.Wedidnot perform
International Society ofUrological Pathology–standard regrading. Thus,
many of the patients graded as Gleason score 6 during the period from
1996 to 2005 might be graded as Gleason score 7 using the modified
Gleason system.
Active surveillance for favorable-risk and select early intermediate-
risk prostate cancer is feasible and seems to be safe over 15 years.
This strategy provides the benefit of a personalized approach based
on the demonstrated risk of clinical or biochemical progression
with time. In this cohort, the likelihood of dying of other causes
was 9.2 times greater than the likelihood of prostate cancer death.
Although prostate cancer mortality increased with longer follow-
up, only 2.8% of patients have developed metastatic disease and
1.5% have died of prostate cancer. These findings are consistent
with expected mortality in favorable-risk patients managed with
initial definitive intervention.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
Disclosures provided by the authors are available with this article at
www.jco.org.
AUTHOR CONTRIBUTIONS
Conception and design: Laurence Klotz, Danny Vesprini, Andrew
Loblaw
Collection and assembly of data: Laurence Klotz, Perakaa Sethukavalan,
Vibhuti Jethava, Suneil Jain, Toshihiro Yamamoto, Alexandre Mamedov,
Andrew Loblaw
Data analysis and interpretation: Laurence Klotz, Danny Vesprini,
Liying Zhang, Suneil Jain, Andrew Loblaw
Manuscript writing: All authors
Final approval of manuscript: All authors
REFERENCES
1. Choo R, Klotz L, Danjoux C, et al: Feasibility
study: Watchful waiting for localized low to interme-
diate grade prostate carcinoma with selective de-
layed intervention based on prostate specific
antigen, histological and/or clinical progression. J
Urol 167:1664-1669, 2002
2. Klotz L: Active surveillance for prostate can-
cer: For whom? J Clin Oncol 23:8165-8169, 2005
3. Klotz L, Zhang L, Lam A, et al: Clinical results
of long-term follow-up of a large, active surveillance
cohort with localized prostate cancer. J Clin Oncol
28:126-131, 2010
4. Remzi M, Fong YK, Dobrovits M, et al: The
Vienna nomogram: Validation of a novel biopsy
strategy defining the optimal number of cores based
on patient age and total prostate volume. J Urol
174:1256-1260, 2005
5. Altman DG, De Stavola BL, Love SB, et al:
Review of survival analyses published in cancer
journals. Br J Cancer 72:511-518, 1995
6. Zhang L, Loblaw A, Klotz L: Modeling prostate
specific antigen kinetics in patients on active surveil-
lance. J Urol 176:1392-1397, 2006
7. Albertsen PC, Hanley JA, Fine J: 20-year
outcomes following conservative management of
clinically localized prostate cancer. JAMA 293:2095-
2101, 2005
8. van As NJ, Norman AR, Thomas K, et al:
Predicting the probability of deferred radical treat-
ment for localised prostate cancer managed by
active surveillance. Eur Urol 54:1297-1305, 2008
9. Carter HB, Kettermann A, Warlick C, et al:
Expectant management of prostate cancer with
curative intent: An update of the Johns Hopkins
experience. J Urol 178:2359-2364, 2007
10. Soloway MS, Soloway CT, Williams S, et al:
Active surveillance: A reasonable management al-
ternative for patients with prostate cancer—The
Miami experience. BJU Int 101:165-169, 2008
11. Roemeling S, Roobol MJ, de Vries SH, et al:
Active surveillance for prostate cancers detected in
three subsequent rounds of a screening trial: Char-
acteristics, PSA doubling times, and outcome. Eur
Urol 51:1244-1250, 2007
12. Khatami A, Aus G, Damber JE, et al: PSA
doubling time predicts the outcome after active
surveillance in screening-detected prostate cancer:
Results from the European randomized study of
screening for prostate cancer, Sweden section. Int J
Cancer 120:170-174, 2007
13. Popiolek M, Rider JR, Ondren O, et al: Natural
history of early localized prostate cancer: A final
report from three decades of follow up. Eur Urol
63:428-435, 2013
14. Vickers AJ, Savage C, O’Brien MF, et al:
Systematic review of pretreatment prostate-
specific antigen velocity and doubling time as
predictors for prostate cancer. J Clin Oncol 27:
398-403, 2009
15. Loblaw A, Zhang L, Lam A, et al: Comparing
prostate specific antigen triggers for intervention in
men with stable prostate cancer on active surveil-
lance. J Urol 184:1942-1946, 2010
16. Kane CJ, Im R, Amling CL, et al: Outcomes
after radical prostatectomy among men who are
candidates for active surveillance: Results from the
SEARCH database. Urology 76:695-700, 2010
17. Lukka H, Hayter C, Julian JA, et al: Random-
ized trial comparing two fractionation schedules for
patients with localized prostate cancer. J Clin Oncol
23:6132-6138, 2005
18. Efron B: Bootstrap methods: Another look at
the jackknife. Ann Statist 7:1-26, 1979
■ ■ ■
Klotz et al
276 © 2014 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by Queen's University Belfast on January 29, 2018 from 143.117.193.021
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
GLOSSARY TERMS
active surveillance: an approach to management of sus-
pected or proven malignancy felt to pose a low risk of progres-
sion in the short to intermediate term. Tumors are observed
closely with blood tests, imaging, and/or serial biopsy, and inter-
vention is undertaken if/when there is evidence of tumor growth
or progression.
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Appendix
Table A1. Clinical Stage Distribution
Clinical Tumor Stage at Baseline
Total Patients
Patients by Age
 70 Years  70 Years
No. % No. % No. %
T1a 17 1.7 12 2.0 5 1.2
T1b 31 3.1 17 2.9 14 3.5
T1c 739 74. 462 77.5 277 69.6
T2 3 0.3 2 0.3 1 0.2
T2a 126 12.7 61 10.2 65 16.3
T2b 25 2.5 8 1.3 17 4.2
T2c 15 1.5 7 1.1 8 2.0
Unknown 37 3.7 26 4.3 11 2.7
Total 993 595 398
Table A2. Univariable and Multivariable Logistic Regression Analysis of Factors Predicting for Therapeutic Intervention and Comparing Final Multivariable Model
Estimations on SE of Predictive Factors Using the Original Data and 1,000 Bootstrapping Samples
Predictive Factor P Odds Ratio 95% CI
Univariable analysis
Age at baseline .0042 1.026 1.008 to 1.044
T stage at baseline ( v  T2) .0002 1.955 1.377 to 2.762
Gleason score at baseline ( v  6) .0053 1.724 1.170 to 2.517
Log of PSA at baseline (continuous variable)  .001 1.721 1.294 to 2.306
Gleason 4 pattern (yes v no) .0029 1.795 1.216 to 2.628
Gleason score on confirmatory biopsy at 1 year  .001 3.771 2.439 to 5.996
Short PSA DT  3 years (yes v no)  .001 6.286 4.012 to 10.020
Greatest % of cores involved at first biopsy  .001 1.013 1.005 to 1.021
Prostatitis on first biopsy (yes v no) .0531 0.681 0.456 to 0.996
No. of cores on confirmatory biopsy at 1 year  .001 1.400 1.244 to 1.583
Greatest % of cores on confirmatory biopsy at 1 year .0204 1.012 1.002 to 1.022
Multivariable analysis
Gleason score on confirmatory biopsy at 1 year  .001 3.375 2.171 to 5.399
Log of PSA at baseline (continuous variable) .0461 1.781 1.018 to 3.180
Internal validation using original data and 1,000 bootstrapping samples
Gleason score on confirmatory biopsy at 1 year
Original SE 0.232
Bootstrap SE 0.247
Log of PSA at baseline (continuous variable)
Original SE 0.289
Bootstrap SE 0.328
Abbreviation: DT, doubling time; PSA, prostate-specific antigen.
Short PSA DT  3 years was excluded in the multivariable logistic regression analysis because it was a criteria for treatment.
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Table A3. Univariable and Multivariable Logistic Regression Analysis of Factors Predicting for PSA Failure After Definitive Therapy After Initial Surveillance and
Comparing Final Multivariable Model Estimations on SE of Predictive Factors Using Original Data and 1,000 Bootstrapping Samples
Variable P Odds Ratio 95% CI
Univariable analysis
Age at baseline .0224 1.038 1.006 to 1.073
T stage at baseline ( v  T2) .0085 2.139 1.190 to 3.714
Log of PSA at baseline (continuous variable) .0109 1.999 1.185 to 3.444
Gleason score at baseline .3174 1.279 0.774 to 2.022
Gleason score  v  6 at baseline .0145 2.150 1.129 to 3.885
Gleason score on confirmatory biopsy at 1 year .0081 2.266 1.221 to 4.171
Gleason score before intervention .9902 0.998 0.698 to 1.413
No. of biopsies .7571 1.043 0.793 to 1.349
Short PSA DT  3 years (yes v no)  .001 7.801 4.393 to 13.667
Duration on active surveillance (years)  .001 0.817 0.738 to 0.894
No. of cores involved on confirmatory biopsy at first time .1356 1.070 0.962 to 1.162
No. of cores involved before intervention .8792 0.996 0.918 to 1.036
Greatest % of cores involved at first time .0719 1.012 0.998 to 1.026
No. of cores involved on confirmatory biopsy at 1 year .0074 1.308 1.069 to 1.592
Greatest % of cores on confirmatory biopsy at 1 year .0305 1.018 1.001 to 1.035
Multivariable analysis
Duration of active surveillance  .001 0.809 0.730 to 0.887
Log of PSA at baseline (continuous variable) .0140 1.945 1.156 to 3.344
Internal validation using original data and 1,000 bootstrapping samples
Duration of active surveillance
Original SE 0.050
Bootstrap SE 0.051
Log of PSA at baseline (continuous variable)
Original SE 0.271
Bootstrap SE 0.252
Abbreviation: DT, doubling time; PSA, prostate-specific antigen.
Short PSA DT  3 years was excluded in the multivariable logistic regression analysis because it was a criteria for treatment.
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Fig A1. Kaplan-Meier cause-specific survival curves stratified by age less than or  70 years (log-rank test, P  .13).
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Fig A2. Cumulative hazard ratio of non–prostate cancer death (blue line) to prostate cancer death (gold line).
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Fig A3. Cumulative hazard of non–prostate cancer death stratified by age  70 years (blue line) or by age less than 70 years (gold line) and of prostate cancer death
stratified by age  70 years (gray line) or by age less than 70 years (red line).
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Fig A4. Time from treatment to prostate-specific antigen (PSA) failure (treated patients only).
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